ArticleFrontiers in medicine2026
The
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent research on the use of the MPT64 antigen of Methods: We included a total of 176 patients, divided into a pulmonary tuberculosis (PTB) group of 104 cases and a non-tuberculosis (Non-TB) group of 72 cases as the control group. The PTB group includes 59 with bacteriologically confirmed PTB (BC-PTB) and 45 with clinically diagnosed PTB with negative pathogens (CD-PTB). The concentrations of MPT64 antigens were detected by enzyme-linked immunosorbent assay (ELISA). Optimal cut-off values were determined by receiver operating characteristic (ROC) curves to evaluate antigen diagnostic capability for active PTB, compared with acid-fast bacilli (AFB) and Xpert MTB/RIF. Results: Xpert MTB/RIF Ct values and MPT64 concentration show significant negative correlation ( Conclusion: The use of ELISA to detect the MPT64 in BALF may serve as an important supplementary diagnostic method for pulmonary tuberculosis, particularly for bacterial-negative pulmonary tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.